Killed Corynebacterium parvum Vaccine Adjuvant |
|
Vaxjo ID |
30 |
|
Vaccine Adjuvant Name |
Killed Corynebacterium parvum Vaccine Adjuvant |
|
Adjuvant VO ID |
VO_0001259
|
|
Description |
It has since been shown that C. parvum acts as an adjuvant and that treatment of animals with this organism can protect them from tumour-cell, protozoal and bacterial challenge. Protection is also afforded against graft-versus-host disease (Adlam and Scott, 1973). |
|
Stage of Development |
Clinical Trial |
|
Preparation |
Heat-killed suspensions of C. paruum were prepared according to the method described by Halpern. A lyophilized culture of C. parvum was obtained from the American Type Culture Collection. Following reconstitution in brain, liver, heart semi-solid medium,o incubation at 37 C was carried out for 4-10 days in a GasPak Disposable Anaerobic System. After centrifugation at 2000 rpm, the sediment was resuspended in saline and heated to 65 C for one hour. After respinning, the killed bacteria were weighed wet and then resuspended in saline at a concentration of 2.5 ml/mg. After adding 2% formalin as a preservative, the final product was stored in sterile containers at 4 C until used (Fisher et al., 1970). |
|
Dosage |
Groups of mice were given varying numbers of injections (0.5 mg) of bacterial suspension by various routes. One group received 0.5 mg of Corynebacterium subcutaneously on alternate days, and the other received saline (Fisher et al., 1970). |
|
Function |
The work of Privot and Tran Van Phi (1964), who showed that several diphtheroid species other than C. parvum stimulate the reticulo-endothelial system to take up injected carbon more rapidly, suggested that the properties possessed by C. parvum might be common to several related species. It may also be satisfactorily substituted for the mycobacterial component of Freund's complete adjuvant (Adlam and Scott, 1973). |
|
Safety |
These results also demonstrate that Corynebacterium suspensions can be given safely to rodents without detectable local or systemic reactions if administered subcutaneously. Nevertheless, observed allergic reactions following intravenous or intraperitoneal administrations suggest that this agent may be a potent allergen and should be used with care during any clinical trial.(Fisher et al., 1970) |
| Related Vaccine(s) |
|
| References |
Adlam and Scott, 1973: Adlam C, Scott MT. Lympho-reticular stimulatory properties of Corynebacterium parvum and related bacteria. Journal of medical microbiology. 1973; 6(3); 261-274. [PubMed: 4726332].
Fisher et al., 1970: Fisher JC, Grace WR, Mannick JA. The effect of nonspecific immune stimulation with corynebacterium parvum on patterns of tumor growth. Cancer. 1970; 26(6); 1379-1382. [PubMed: 5483667].
|
